- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05303467
Une étude de faisabilité pour évaluer la sécurité du dispositif TheraSphere Glioblastoma (GBM) chez les patients atteints de GBM récurrent (FRONTIER)
FRONTIER : Une étude de faisabilité pour évaluer l'innocuité du dispositif TheRaSphere GliOblastoma (GBM) chez les patients atteints de GBM récurrent
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Glioblastoma (GBM) is a highly aggressive brain cancer with a grave prognosis, resulting in <7% of patients surviving to five years post-diagnosis. External beam radiotherapy (EBRT) is currently a mainstay treatment for GBM; however, the dose delivered is limited by side effects. The targeted radiotherapy of the TheraSphere GBM Y-90 Glass Microsphere System (TheraSphere GBM) has promising potential to provide GBM patients with reduced side effects compared to external beam radiotherapy as well as a more effective treatment for this catastrophic disease.
The TheraSphere GBM device utilized in the FRONTIER trial is an yttrium-90 (Y-90) glass microsphere therapy for selective internal radiation therapy (endovascular radiotherapy) in recurrent GBM patients. The TheraSphere GBM treatment utilizes intra-arterial delivery and takes advantage of blood flow and direct tumor delivery. Treatment can be delivered by specific placement of a catheter close to the tumor through known angiographic techniques currently utilized by neuro-endovascular or interventional radiology physicians. Angiographic evaluation prior to treatment allows identification of tumor feeding arteries and definition of the treatment volume. TheraSphere GBM could achieve a high tumor response rate based on delivery of a tumor absorbed dose that is not currently possible with EBRT.
In consideration of the potential benefit of a more localized, targeted treatment with a reduced side effect profile compared to other treatment options, and the potential impact on patients' quality of life for this devastating disease, this First-in-Human Early Feasibility Study (EFS) of the TheraSphere GBM Y-90 Glass Microsphere System for the treatment of recurrent GBM is being conducted.
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Sally Linda
- Numéro de téléphone: 952-201-3102
- E-mail: Sally.Linda@bsci.com
Sauvegarde des contacts de l'étude
- Nom: Lilian Liu Pan
- Numéro de téléphone: 858-888-5682
- E-mail: Lilian.LiuPan@bsci.com
Lieux d'étude
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294
- Retiré
- University of Alabama Birmingham
-
-
California
-
San Diego, California, États-Unis, 92103
- Recrutement
- University of California San Diego
-
Chercheur principal:
- Zachary Berman, MD
-
Contact:
- Sheila Medina Torne
- Numéro de téléphone: 858-822-6100
- E-mail: s4medina@health.ucsd.edu
-
San Francisco, California, États-Unis, 94143
- Recrutement
- University of California San Francisco
-
Chercheur principal:
- Nicholas Butowski, MD
-
Contact:
- Stephanie Lewis
- Numéro de téléphone: 415-353-2193
- E-mail: NeuroOncNewPatientCoord@ucsf.edu
-
-
Florida
-
Jacksonville, Florida, États-Unis, 32224
- Recrutement
- Mayo Jacksonville
-
Chercheur principal:
- Alfredo Quinones-Hinojosa, MD
-
Contact:
- Aleeshba Basil
- Numéro de téléphone: 855-776-0015
- E-mail: Basil.aleeshba@mayo.edu
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Northwestern Univerity
-
Contact:
- Roger Stupp, MD
- Numéro de téléphone: 866-587-4322
- E-mail: roger.stupp@northwestern.edu
-
Chercheur principal:
- Samdeep Mouli, MD
-
Contact:
- Emily R Powell
- Numéro de téléphone: 312-926-3872
- E-mail: emily.powell@northwestern.edu
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Retiré
- Johns Hopkins Interventional Radiology Center
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63130
- Recrutement
- Washington University School of Medicine
-
Contact:
- Rachel Reed
- E-mail: Rachel.Reed@wustl.edu
-
Chercheur principal:
- Arindam Chatterjee, M.D.
-
-
New York
-
New York, New York, États-Unis, 10075
- Recrutement
- Lenox Hill Hospital
-
Contact:
- Tamika Wong
- Numéro de téléphone: 212-434-4836
- E-mail: twong4@northwell.edu
-
Chercheur principal:
- John Boockvar, MD
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- MD Anderson Cancer Center
-
Contact:
- Summer Stovall
- Numéro de téléphone: 713-745-4243
- E-mail: SStovall@mdanderson.org
-
Chercheur principal:
- Stephen Chen, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Subject is 18 years or older and has signed and dated the trial informed consent form (ICF)
-
Life expectancy ≥ 12 weeks
-
Subject is willing and able to comply with the trial testing, procedures, and follow-up schedule
-
History of a histologically confirmed diagnosis of glioblastoma per 2021 WHO criteria
-
Have radiographic evidence of tumor progression/recurrence with measurable disease (≥ 1 cm to ≤ 5cm bidirectional diameters) by contrast-enhancement on MRI, according to RANO criteria
-
Prior surgery and treatment with combination of radiotherapy and chemotherapy ± Tumor Treating Fields (Optune®)
-
Prior cranial radiation dose < 66 Gy
-
WHO performance status ≤ 2
-
The interval since completion of cranial radiotherapy must be > 6 months, unless there is tissue confirmation of tumor recurrence/progression outside the previous radiation treatment field, in which case the interval since completion of cranial radiation must be at least 12 weeks
-
Interval since last systemic therapy until presumed date of intervention ≥ 1 cycle or ≥ 2 biological half-lives, i.e.
- ≥ 4 weeks since last dose of temozolomide
- ≥ 6 weeks since last dose of lomustine or other nitrosourea
- ≥ 2 weeks since last dose of a small molecule targeted agent (Tyrosine Kinase Inhibitor or similar)
- ≥ 6 weeks from last dose of last intravenous bevacizumab infusion, or other antibody-based VEGF therapy
-
If receiving steroids, patient should be on a stable or decreasing dose equivalent to dexamethasone ≤ 6 mg/d, for at least 7 days prior to registration
-
Have adequate organ and bone marrow function within 14 days prior to registration, as defined below:
- INR ≤ 1.2 (in absence of anticoagulation)
- Platelets ≥ 100,000/L
- Creatinine ≤1.5 mg/dL
- Absolute Neutrophil Count ≥1.5 x 10^9/L
- Hemoglobin ≥9.0 g/dL
-
Have a negative pregnancy test within 14 days prior to registration on study (for FOCBP, female of child-bearing potential)
-
Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active must be using, or agree to use, a medically acceptable method of birth control as confirmed by the investigator
-
Angiographic Mapping Inclusion Criteria:
- Accessible neurovascular anatomy that allows for safe microcatheter placement (up to two locations) to infuse TheraSphere GBM to treat all of the T1 enhancing component of target lesion confirmed by neuro-interventional team.
- Total treatment volume is ≤ 150cc as determined by multidisciplinary team.
-
Additional Inclusion Criteria:
- Group A: perfused volume encompasses the non-dominant hemisphere and non-eloquent regions of the brain
- Group B: perfused volume encompasses the non-dominant hemisphere and eloquent regions of the brain
- Group C: perfused volume encompasses the dominant hemisphere and non-eloquent regions of the brain
- Group D: perfused volume encompasses the dominant hemisphere and eloquent regions of the brain
Exclusion Criteria:
-
Have bilateral gadolinium enhancing disease, tumor located in the posterior fossa, tumor involving critical subcortical structures (thalamus/hypothalamus, midbrain, brainstem, corticospinal tract, internal capsule, cerebral peduncle), tumor approximating or invading the brainstem and/or optic chiasma, leptomeningeal disease, or extracranial metastatic disease
-
Have received more than 1 course of prior cranial radiotherapy (EBRT)
-
Have received radiosurgery, brachytherapy, or hypofractionated radiotherapy
-
Have received more than 2 systemic treatment protocols (lines of treatment), not including maintenance temozolomide
-
Have received prior intra-arterial cerebral infusion therapy
-
Have received more than 2 surgical GBM-related procedures
-
Have received prior thoracic radiation therapy
-
Are at increased risk of wound dehiscence by the discretion of the investigators (e.g. brain surgery within the last 3 months, poor skin condition, and/or previously infected surgical field or any other condition that is of increased infectious risk in the opinion of the neurosurgeon)
-
Have uncontrolled epilepsy
-
Have severe and/or insufficiently controlled intercurrent illness; patients with the following are not eligible:
- Hypertension grade 3 or higher without adequate control on medications
- Symptomatic or unstable cardiac disease, known to have right-to-left shunts, or severe pulmonary hypertension (pulmonary artery pressure > 90 mmHg)
- Pulmonary insufficiency (arterial oxygen pressure (Pa,O2) of < 60 mmHg, or oxygen saturation (Sa,O2) of < 90%) as measured by fingertip pulse oximeter
- Ongoing or active bacterial or viral infection requiring systemic treatment (including HIV)
- Pneumonitis
- Psychiatric illness/social situations that would limit compliance with study requirements
- Peripheral Neuropathy ≥ grade 1
- Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety, study endpoints or longevity
-
Are currently pregnant or breast feeding (unless patient agrees to stop breastfeeding)
-
Patients with a history of an active other malignancy within 1 year prior to registration. NOTE: Exceptions to this requirement include adequately treated non-melanoma skin cancer or lentigo maligna or carcinoma in situ without evidence of disease, or recurrent glioblastoma
-
Patients with a history of ischemic cerebral disease and/or at risk of cerebral herniation
-
Medical contraindication to undergo contrast-enhanced magnetic resonance imaging (MRI)
-
Known history of hypersensitivity reactions to iodinated and/or gadolinium-based contrast
-
Subject has received any other investigational agents within 4 weeks of treatment, or is currently participating, or plans to participate in, another investigational trial that may confound the results of this trial (unless written approval is received from the Boston Scientific study team)
-
Angiographic Mapping Exclusion Criteria: Patients with significant vascular disease, significant AV shunting, or anatomic tortuosity on MR/CT Angiogram precluding safe or feasible vascular access
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment Group A
Subjects in which the perfused volume encompasses the non-dominant hemisphere and non-eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%. |
Single treatment of TheraSphere GBM device
Autres noms:
|
|
Expérimental: Treatment Group B
Subjects in which the perfused volume encompasses the non-dominant hemisphere and eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%. |
Single treatment of TheraSphere GBM device
Autres noms:
|
|
Expérimental: Treatment Group C
Subjects in which the perfused volume encompasses the dominant hemisphere and non-eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%. |
Single treatment of TheraSphere GBM device
Autres noms:
|
|
Expérimental: Treatment Group D
Subjects in which the perfused volume encompasses the dominant hemisphere and eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%. |
Single treatment of TheraSphere GBM device
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Le nombre de toxicités non hématologiques de grade 3 à 5
Délai: 30 jours après la procédure d'indexation
|
30 jours après la procédure d'indexation
|
|
Le nombre de toxicités du SNC de grade ≥ 3 liées à une embolisation non ciblée
Délai: 30 jours après la procédure d'indexation
|
30 jours après la procédure d'indexation
|
|
Apparition d'une radionécrose cérébrale symptomatique nécessitant une intervention médicale ou chirurgicale et confirmée par une pathologie
Délai: 30 jours après la procédure d'indexation
|
30 jours après la procédure d'indexation
|
|
Le nombre d'événements de neutropénie de grade 4 persistant pendant plus de 5 jours
Délai: 30 jours après la procédure d'indexation
|
30 jours après la procédure d'indexation
|
|
Le nombre de neutropénies fébriles de grade 4
Délai: 30 jours après la procédure d'indexation
|
30 jours après la procédure d'indexation
|
|
Le nombre de thrombocytopénies de grade 4 ou de thrombocytopénies de grade 3 avec hémorragie
Délai: 30 jours après la procédure d'indexation
|
30 jours après la procédure d'indexation
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Taux d'événements indésirables liés au traitement et d'événements indésirables graves liés au traitement (sans compter les toxicités limitantes prédéfinies) depuis le premier patient inscrit jusqu'à la fin de l'étude.
Délai: Inscription à travers 6 mois après la procédure d'indexation
|
Inscription à travers 6 mois après la procédure d'indexation
|
|
|
Taux de réponse objective* (ORR) du premier patient inscrit jusqu'à la fin de l'étude
Délai: Inscription à travers 6 mois après la procédure d'indexation
|
Inscription à travers 6 mois après la procédure d'indexation
|
|
|
Survie sans progression* (SSP) du premier patient inscrit jusqu'à la fin de l'étude
Délai: Inscription à travers 6 mois après la procédure d'indexation
|
Inscription à travers 6 mois après la procédure d'indexation
|
|
|
Survie globale (SG) du premier patient inscrit jusqu'à la fin de l'étude
Délai: Inscription à travers 6 mois après la procédure d'indexation
|
Inscription à travers 6 mois après la procédure d'indexation
|
|
|
Succès technique / faisabilité de Therasphere GBM - Capacité à fournir la dose absorbée par les rayonnements projetée (+/- 20%) au volume perfusé pour tous les patients traités avec l'appareil. Évalué à partir de la pré-dépistage via la livraison post-appareils PET-CT / IRM.
Délai: Pré-dépréciation via la livraison post-appareils PET-CT / IRM.
|
Pré-dépréciation via la livraison post-appareils PET-CT / IRM.
|
|
|
Change in post-treatment neurological function as assessed by the National Institute of Health Stroke Scale (NIHSS).
Délai: Enrollment through 6 months post index procedure
|
The NIHSS is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. |
Enrollment through 6 months post index procedure
|
|
Change in post-treatment neurological function as assessed by the modified Rankin Scale (mRS).
Délai: Enrollment through 6 months post index procedure
|
The mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability on a scale from 0 (no symptoms at all) to 6 (death). |
Enrollment through 6 months post index procedure
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Riad Salem, M.D., Northwestern University
- Chercheur principal: Roger Stupp, M.D., Northwestern University
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- S2478
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .